Poeschla Michael, Arora Uma P, Walne Amanda, McReynolds Lisa J, Niewisch Marena R, Giri Neelam, Zeigler Logan P, Gusev Alexander, Machiela Mitchell J, Tummala Hemanth, Savage Sharon A, Sankaran Vijay G
Division of Hematology/Oncology, Boston Children's Hospital, Boston, United States of America.
Genomics and Child Health, Queen Mary University of London, London, United Kingdom.
J Clin Invest. 2025 Jun 3. doi: 10.1172/JCI191107.
BACKGROUND: Telomere biology disorders (TBDs) exhibit incomplete penetrance and variable expressivity, even among individuals harboring the same pathogenic variant. We assessed whether common genetic variants associated with telomere length combine with large-effect variants to impact penetrance and expressivity in TBDs. METHODS: We constructed polygenic scores (PGS) for telomere length in the UK Biobank to quantify common variant burden, and assessed the PGS distribution across patient cohorts and biobanks to determine whether individuals with severe TBD presentations have increased polygenic burden causing short telomeres. We also characterized rare TBD variant carriers in the UK Biobank. RESULTS: Individuals with TBDs in cohorts enriched for severe pediatric presentations have polygenic scores predictive of short telomeres. In the UK Biobank, we identify carriers of pathogenic TBD variants who are enriched for adult-onset manifestations of TBDs. Unlike individuals in disease cohorts, the PGS of adult carriers do not show a common variant burden for shorter telomeres, consistent with the absence of childhood-onset disease. Notably, TBD variant carriers are enriched for idiopathic pulmonary fibrosis diagnoses, and telomere length PGS stratifies pulmonary fibrosis risk. Finally, common variants affecting telomere length were enriched in enhancers regulating known TBD genes. CONCLUSION: Common genetic variants combine with large-effect causal variants to impact clinical manifestations in rare TBDs. These findings offer a framework for understanding phenotypic variability in other presumed monogenic disorders. FUNDING: This work was supported by National Institutes of Health grants R01DK103794, R01HL146500, R01CA265726, R01CA292941, and the Howard Hughes Medical Institute.
背景:端粒生物学障碍(TBDs)表现出不完全外显率和可变表达性,即使在携带相同致病变异的个体中也是如此。我们评估了与端粒长度相关的常见遗传变异是否与大效应变异相结合,以影响TBDs的外显率和表达性。 方法:我们在英国生物银行构建了端粒长度的多基因评分(PGS),以量化常见变异负担,并评估患者队列和生物银行中的PGS分布,以确定严重TBD表现的个体是否具有增加的导致短端粒的多基因负担。我们还对英国生物银行中罕见的TBD变异携带者进行了特征分析。 结果:在严重儿科表现丰富的队列中,患有TBDs的个体具有预测短端粒的多基因评分。在英国生物银行中,我们识别出致病性TBD变异的携带者,他们在TBDs的成人发病表现中富集。与疾病队列中的个体不同,成人携带者的PGS没有显示出短端粒的常见变异负担,这与无儿童期发病疾病一致。值得注意的是,TBD变异携带者在特发性肺纤维化诊断中富集,并且端粒长度PGS对肺纤维化风险进行分层。最后,影响端粒长度的常见变异在调节已知TBD基因的增强子中富集。 结论:常见遗传变异与大效应因果变异相结合,影响罕见TBDs的临床表现。这些发现为理解其他假定的单基因疾病的表型变异性提供了一个框架。 资助:这项工作得到了美国国立卫生研究院R01DK103794、R01HL146500、R01CA265726、R01CA292941拨款以及霍华德·休斯医学研究所的支持。
J Clin Invest. 2025-6-3
JAMA Netw Open. 2024-12-2
J Clin Invest. 2025-8-15
JAMA Netw Open. 2024-12-2
EMBO Mol Med. 2024-10